|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ChiCTR |
|
Last refreshed on:
|
16 May 2022 |
|
Main ID: |
ChiCTR2100050948 |
|
Date of registration:
|
2021-09-08 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Comparison of clinical efficacy and safety of hematopoietic stem cell transplantation and immunosuppression in the treatment of hepatitis-related aplastic anemia: a single-center cohort study
|
|
Scientific title:
|
Comparison of clinical efficacy and safety of hematopoietic stem cell transplantation and immunosuppressive therapy in patients with hepatitis-related aplastic anemia |
|
Date of first enrolment:
|
2021-09-10 |
|
Target sample size:
|
ematopoietic stem cell transplantation group:30;ATG combined with cyclosporine group :30; |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://www.chictr.org.cn/showproj.aspx?proj=133305 |
|
Study type:
|
Observational study |
|
Study design:
|
Non randomized control
|
|
Phase:
|
Retrospective study
|
|
|
Countries of recruitment
|
|
China
| | | | | | | |
|
Contacts
|
|
Name:
|
Wu Dijiong
|
|
Address:
|
54 Youdian Road, Hangzhou, Zhejiang
310006
|
|
Telephone:
|
+86 571 86620325 |
|
Email:
|
wdj850@163.com |
|
Affiliation:
|
Zhejiang Provincial Hospital of Traditional Chinese Medicine |
|
|
Name:
|
Wu Dijiong
|
|
Address:
|
54 Youdian Road, Hangzhou, Zhejiang
310006
|
|
Telephone:
|
+86 571 86620325 |
|
Email:
|
wdj850@163.com |
|
Affiliation:
|
Zhejiang Provincial Hospital of Traditional Chinese Medicine |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Diagnosed with hepatitis-related aplastic anemia, hepatitis-related aplastic anemia is aplastic anemia that occurs within 6 months after the onset of acute hepatitis;
2. Those who have participated in or are participating in other clinical trials within the past three months.
Exclusion criteria: 1. Paroxysmal nocturnal hemoglobinuria (PNH) clone with obvious clinical or biochemical evidence of hemolysis;
2. Unable to receive IST or HSCT treatment due to concurrent dysfunction of other systems or organs.
Age minimum:
1
Age maximum:
50
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Hepatitis-associated Aplastic Anemia
|
|
Intervention(s)
|
|
ematopoietic stem cell transplantation group:Nil;ATG combined with cyclosporine group :Nil;
|
|
Primary Outcome(s)
|
|
efficacy;blood routine;bone marrow smear;lymphocyte subsets;safety;
|
|
Secondary Outcome(s)
|
|
ferritins;
|
|
Source(s) of Monetary Support
|
|
Self-funded, National Key Disciplines Funding
|
|
Ethics review
|
Status: Not approved
Approval date: 26/08/2013
Contact:
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|